Months after a monstrous blowup, a closely watched biotech sets its sights on gene therapy
by Damian Garde
Jun 06, 2018
2 minutes
If you bet $100 on Axovant Sciences nine months ago, you’re down 93 bucks. But the biotech company best known for a blowup rivaling bitcoin wants a second chance, and on Wednesday is unveiling new management and a new drug it believes can win investors back over.
Axovant, founded by biotech entrepreneur , is pivoting to gene therapy. The company paid $30 million up front for a
You’re reading a preview, subscribe to read more.
Start your free 30 days